Genzyme: Why Diversification is Starting to Look Smart

As the blockbuster model comes under threat, Genzyme's highly diversified approach begins to look smart. Plenty of larger companies likely envy Genzyme's specialist expertise, tight customer relationships and long-standing embrace of external R&D. It's up to CEO Henri Termeer to prove that these strengths warrant an independent future for Genzyme.

Melanie Senior

Like most Big Biotechs, Genzyme Corp. has been associated with one major drug—its Gaucher’s disease treatment imiglucerase (Cerezyme). With sales of more than $1 billion--almost 30% of Genzyme’s total revenues--the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo